Loading candles…
Molbio Diagnostics Limited is an Indian medical diagnostics company headquartered in Verna, Goa, specializing in molecular diagnostic technologies. Founded in 2000, the company developed Truenat, a portable real-time PCR platform for diagnosing infectious diseases such as tuberculosis, HIV, and hepatitis. Truenat is endorsed by the World Health Organization for initial detection of tuberculosis and rifampicin resistance. The company has expanded its portfolio to include advanced digital radiology and pathology solutions. As of 2025, Molbio reported a revenue of ₹1,027.94 crore and employed approximately 616 people.
This page is a live market overview for MOLBIO DIAGNOSTICS LTD (MOLBIO) on the NSE. As a listed security, MOLBIO DIAGNOSTICS LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for MOLBIO before placing trades on tick2trade.
As of the latest feed, MOLBIO last traded at ₹1,223.5 on NSE, down ₹22.7 (1.82%) from the previous close of ₹1,246.2. Today's session range is ₹1,216.6 – ₹1,258.5, against a 52-week band of ₹926.35 – ₹1,686.8. Traded volume today stands at 1.88L shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for MOLBIO in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether MOLBIO is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for MOLBIO DIAGNOSTICS LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in MOLBIO. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated MOLBIO option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Unaudited Results - Q1-FY26 | To consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026. | 5 Sep 2026 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.